Isoliquiritigenin restores bone homeostasis in osteoporotic rats by enhancing BMSCs osteogenesis via ERK1/2-mTOR-HIF-1α-glycolytic axis and suppressing inflammation - PubMed
3 hours ago
- #osteoporosis
- #inflammation
- #BMSCs
- Isoliquiritigenin (ISL) promotes osteogenic differentiation and suppresses adipogenic differentiation of BMSCs.
- ISL activates the ERK1/2-mTOR-HIF-1α signaling axis, enhancing glycolysis to support osteogenesis.
- ISL remodels the inflammatory bone marrow microenvironment by reducing oxidative stress and pro-inflammatory cytokines.
- ISL reprograms macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotype.
- In a rat ovariectomy model, ISL attenuated bone loss, reduced marrow adiposity, and decreased inflammation.
- ISL is a promising therapeutic candidate for osteoporosis by restoring bone homeostasis.